AGP Picks
View all

GO2 for Lung Cancer and Patient Data Vault launch pilot to improve trial matching

18 hours ago
GO2 for Lung Cancer and Patient Data Vault launch pilot to improve trial matching
By AI, Created 16:43 UTC, Nov 16, 2026, AGP -

GO2 for Lung Cancer and Patient Data Vault have started a pilot collaboration on Nov. 16, 2026, to help lung cancer patients find clinical trials that fit their diagnosis and get support deciding next steps. The effort links GO2’s LungMATCH navigators with PDV’s medical-record-based trial-matching platform and keeps patients in control of what information is shared.

Why it matters: - Lung cancer patients often need to sort through trial options quickly, while eligibility can depend on detailed clinical and biomarker information. - The pilot aims to give patients both trial matching and human navigation support in one workflow. - The collaboration is designed to help patients understand options beyond trial matching, including biomarker results and FDA-approved treatments.

What happened: - GO2 for Lung Cancer and Patient Data Vault announced a pilot collaboration on Nov. 16, 2026. - The pilot connects GO2’s LungMATCH program with PDV’s AI-powered trial-matching platform. - The two organizations are combining their navigation services for people living with lung cancer.

The details: - LungMATCH users can upload medical records to PDV’s platform to receive a personalized report of possible clinical trials. - Those users can then connect with a navigator from GO2, PDV, or both organizations. - PDV users with lung cancer will be connected to GO2 LungMATCH navigators and patient support services. - GO2 support includes help interpreting biomarker results and understanding FDA-approved treatment options. - PDV’s lung cancer report will include access to GO2’s library of peer-reviewed, patient-friendly educational resources. - If a patient chooses to share trial matches, LungMATCH navigators can review them inside PDV’s navigator platform. - PDV care navigators are also available to walk patients through results. - Patients control what information is shared between the organizations. - Medical records are not sold, licensed, or shared without explicit patient authorization. - The pilot begins Nov. 16, 2026.

Between the lines: - The partnership reflects a broader push to reduce friction in clinical trial access by pairing software with person-to-person guidance. - The setup also suggests the companies see value in meeting patients earlier, before trial searching becomes overwhelming or time-sensitive. - The emphasis on patient control appears intended to address privacy concerns that can slow adoption of record-based matching tools.

What’s next: - The pilot will test whether the combined workflow improves how quickly lung cancer patients can identify relevant trials and get help interpreting results. - Success could point to a model for linking disease-specific advocacy groups with digital matching platforms in other cancer types.

The bottom line: - GO2 and PDV are trying to make clinical trial navigation faster, more personal and less dependent on patients doing the search alone.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Healthcare Online Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthcare Online Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.